[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608310":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":26,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":26,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ADH analougue monotherapy","SHAM_COMPARATOR","Desmopressin",[13],"Drug: Desmopressin (DDAVP)",{"label":15,"type":16,"description":17,"interventionNames":18},"Anticholinergic and b3 agonist combination","EXPERIMENTAL","Solifenacin and Mirabegron",[19],"Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mirabegron (beta3-adrenoceptor agonist), Anticholinergics","Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Desmopressin (DDAVP)","ADH analogue in treatment of mono-symptomatic nocturnal enuresis",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Abdelhamid El Sayed Shahin, MBBCH","CONTACT","+201005876463","hameedshahin95@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":26},"Urology and Nephrology center - Mansoura University","RECRUITING","Al Mansurah","Egypt","EG",{"type":45,"coordinates":46},"Point",[47,48],31.38069,31.03637,{"lat":48,"lon":47},{"type":51,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100608310","phase-3-omegapres-versus-solifenacin-and-mirabegron-combination-therapy-in-treatment-of-primary-mne-100608310",false,"NCT07199894","Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE","A Randomized Controlled Trial Comparing Mirabegron and Solifenacin Combination Therapy Versus Desmopressin Monotherapy in Treatment of Children With Primary Mono-Symptomatic Nocturnal Enuresis","Inclusion Criteria:\n\nPrimary mono-symptomatic nocturnal enuresis -\n\nExclusion Criteria:\n\nBowel dysfunction Psychatric illness Respiratory sleep disorders\n\n\\-","ALL","6 Years","18 Years",{"count":63,"type":64},120,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are:\n\nDoes combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis.\n\nParticipants will:\n\nTake the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights",[70],"Nocturnal Enuresis in Children",[72,11,73,74,75,76,77],"nocturnal enuresis","Mirabegron","Solifenacin","B3 agonist","Anti-cholinergic","Randomised controlled trial","2025-09-22",{"date":80,"type":81},"2025-09-30","ACTUAL",{"date":83,"type":81},"2024-12-01",{"date":85,"type":64},"2026-02-01",{"name":5,"class":6},1]